IPA Nov 2024 2.500 put
| Previous close | 1.2500 |
| Open | 1.2500 |
| Bid | 1.1500 |
| Ask | 1.7000 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.2500 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 50 |
Business WireImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
VICTORIA, British Columbia, June 27, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has been serving as Interim CFO since September 19th, 2023, and now transitions into the role on a permanent basis.
Business WireIPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
VICTORIA, British Columbia, June 25, 2024--ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand, is collaborating with PGxAI to leverage BioStrand's patented Foundation AI Model, LENSai. This collaboration advances the precision medicine field of pharmacogenomics and supports LENSai Application Programming Interface ("API") commercial rollout through expanding LENSai featu
Business WireImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
VICTORIA, British Columbia, June 12, 2024--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), a leader in AI-driven biotherapeutic research and technology, today announces that its subsidiary, BioStrand, has been honored with the prestigious 2024 Impact Award, sponsored by InterSystems. This recognition highlights BioStrand’s groundbreaking work in biotherapeutic research, which has made a significant impact and set a new standard for innovation in the indus
